Physician profile
Edgar Camacho
NPI 1841981545
$9,094.95
in general payments reported to CMS, 2019-2025
29 companies · $2,537 in 2025
The $2,537 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,315 · 2024: $4,243 · 2025: $2,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,717 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,717.11 |
| Education | $377.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,179.85 | 2023-2025 | |
| Janssen Biotech, INC. | $1,152.02 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $817.44 | 2023-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $759.30 | 2023-2025 | |
| Pfizer INC. | $655.26 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $532.77 | 2023-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $529.97 | 2023-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $345.07 | 2024-2025 | Acthar |
| Ucb, INC. | $335.48 | 2023-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $230.99 | 2023-2025 | Taltz |
| Sobi, INC | $196.00 | 2024 | |
| Glaxosmithkline, LLC. | $187.13 | 2024-2025 | Benlysta |
| Organon LLC | $151.64 | 2023-2025 | Hadlima, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.90 | 2023-2025 | Ofev, Cyltezo |
| Kiniksa Pharmaceuticals International, Plc | $128.95 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $104.22 | 2023 | Truxima |
| Genzyme Corporation | $90.29 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $87.07 | 2025 | Uptravi, Opsumit, Opsynvi |
| Kyowa Kirin, INC. | $78.77 | 2023-2024 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $54.93 | 2024 | Orencia |
| Octapharma USA, INC. | $49.37 | 2023 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $44.05 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $24.21 | 2025 | Hyqvia |
| Genentech USA, INC. | $24.10 | 2024 | Actemra |
| Fresenius Kabi USA, LLC | $23.47 | 2024 | Idacio |
| Ani Pharmaceuticals, INC. | $18.50 | 2024 | Valsartan |
| Fidia Pharma USA INC. | $18.14 | 2024 | Hym/Hyn |
| Sandoz INC. | $15.06 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.